BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24923637)

  • 1. Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo.
    Kemnade JO; Seethammagari M; Collinson-Pautz M; Kaur H; Spencer DM; McCormick AA
    Vaccine; 2014 Jul; 32(33):4228-33. PubMed ID: 24923637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active dissemination of cellular antigens by DCs facilitates CD8
    Gurevich I; Feferman T; Milo I; Tal O; Golani O; Drexler I; Shakhar G
    Eur J Immunol; 2017 Oct; 47(10):1802-1818. PubMed ID: 28872666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells.
    Ho AW; Prabhu N; Betts RJ; Ge MQ; Dai X; Hutchinson PE; Lew FC; Wong KL; Hanson BJ; Macary PA; Kemeny DM
    J Immunol; 2011 Dec; 187(11):6011-21. PubMed ID: 22043017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
    McCormick AA; Corbo TA; Wykoff-Clary S; Nguyen LV; Smith ML; Palmer KE; Pogue GP
    Vaccine; 2006 Sep; 24(40-41):6414-23. PubMed ID: 16860441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
    Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P; Brocker T
    J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spreading the load: Antigen transfer between migratory and lymph node-resident dendritic cells promotes T-cell priming.
    Mueller SN
    Eur J Immunol; 2017 Oct; 47(10):1798-1801. PubMed ID: 28845904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.
    Chiesa S; Morbelli S; Morando S; Massollo M; Marini C; Bertoni A; Frassoni F; Bartolomé ST; Sambuceti G; Traggiai E; Uccelli A
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17384-9. PubMed ID: 21960443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen presenting capacity of murine splenic myeloid cells.
    Hey YY; Quah B; O'Neill HC
    BMC Immunol; 2017 Jan; 18(1):4. PubMed ID: 28077081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.
    Huck SP; Tang SC; Andrew KA; Yang J; Harper JL; Ronchese F
    Cancer Immunol Immunother; 2008 Jan; 57(1):63-71. PubMed ID: 17609951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.
    Kitano M; Yamazaki C; Takumi A; Ikeno T; Hemmi H; Takahashi N; Shimizu K; Fraser SE; Hoshino K; Kaisho T; Okada T
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):1044-9. PubMed ID: 26755602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
    Ho NI; Camps MGM; de Haas EFE; Ossendorp F
    Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH; Liu C; Wan YH
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.
    Brossart P; Goldrath AW; Butz EA; Martin S; Bevan MJ
    J Immunol; 1997 Apr; 158(7):3270-6. PubMed ID: 9120283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Priming of Herpes Simplex Virus-Specific CD8
    Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique functions of splenic CD8alpha+ dendritic cells during infection with intracellular pathogens.
    Neuenhahn M; Busch DH
    Immunol Lett; 2007 Dec; 114(2):66-72. PubMed ID: 17964665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.
    Hirosue S; Kourtis IC; van der Vlies AJ; Hubbell JA; Swartz MA
    Vaccine; 2010 Nov; 28(50):7897-906. PubMed ID: 20934457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.